Prosecution Insights
Prosecution Insights
6 pending office actions • 2 clients • 5 examiners • 5 art units • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| No statute on record | 4 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, MAUREEN VARINA | 2 | 68.0% | +35.3% |
| PATEL, SAGAR S | 1 | 76.1% | +33.8% |
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
| EDWARDS, JESSICA FAYE | 1 | 44.2% | +46.9% |
| YAO, LEI | 1 | 60.0% | +65.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773240 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | DRISCOLL, MAUREEN VARINA | 259d overdue |
| 17909358 | GUIDANCE AND NAVIGATION CONTROL (GNC) ANTIBODY-LIKE PROTEINSAND METHODS OF MAKING AND USING THEREOF | DRISCOLL, MAUREEN VARINA | 168d overdue |
| 17055561 | COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF | YAO, LEI | 117d overdue |
| 18030757 | Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof | PATEL, SAGAR S | 72d overdue |
| 17772464 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | EDWARDS, JESSICA FAYE | 14d |
| 17909360 | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | KELLY, ROBERT M | 33d |
| Client (Assignee) | Pending OAs |
|---|---|
| Baili-Bio (Chengdu) Pharmaceutical | 5 |
| Arbele | 1 |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1626 | 1 |
| 1638 | 1 |
| 1657 | 1 |
| 1642 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18030757 | Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | PATEL, SAGAR S | 1626 | Other | Non-Final OA | 72d overdue | Pending | Apr 06, 2023 |
| 17909360 | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | KELLY, ROBERT M | 1638 | §112 | Final Rejection | 33d | Pending | Sep 03, 2022 |
| 17909358 | GUIDANCE AND NAVIGATION CONTROL (GNC) ANTIBODY-LIKE PROTEINSAND METHODS OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | DRISCOLL, MAUREEN VARINA | 1644 | — | Non-Final OA | 168d overdue | Pending | Sep 02, 2022 |
| 17773240 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | DRISCOLL, MAUREEN VARINA | 1644 | Other | Non-Final OA | 259d overdue | Pending | Apr 29, 2022 |
| 17772464 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | EDWARDS, JESSICA FAYE | 1657 | Other | Non-Final OA | 14d | Pending | Apr 27, 2022 |
| 17055561 | COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF | Arbele Limited | YAO, LEI | 1642 | §103 | Non-Final OA | 117d overdue | Pending | Nov 13, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial